CellmAbs has entered a significant patent assignment and licensing agreement with BioNTech, potentially marking Portugal's first billion-dollar transaction in the life sciences sector.
Information on the Target
CellmAbs S.A. is a pioneering biotech firm based in Lisbon, Portugal, founded in 2019 by Nuno Prego Ramos and Professor Paula Videira at NOVA University Lisbon. The company specializes in the research and development of novel cancer-specific therapies, particularly focusing on innovative monoclonal antibodies. Its portfolio includes cutting-edge antibody-drug conjugates, bispecific T-cell engagers, and cell therapies, all aimed at targeting cancer-specific antigens.
Supported by Bionova Capital and Portugal Ventures, CellmAbs has successfully developed multiple preclinical candidates through fruitful collaborations with renowned institutions such as the Portuguese Institute of Oncology Porto (IPO) and Helmholtz-Zentrum Dresden-Rossendorf (HZDR) in Germany. This collaboration underscores its commitment to advancing scientific discovery and drug development.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Portugal
The biotech industry in Portugal has shown remarkable growth and potential in recent years, bolstered by a rich academic landscape and a surge in research initiatives. The Portuguese government has r
Similar Deals
BioNTech SE
invested in
CellmAbs S.A.
in 2024
in a Other VC deal